Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

    RICHMOND, VA., June 19 /CNW/ - Insmed Incorporated (NASDAQ:   INSM)
announced today that on June 18, 2007 it received a NASDAQ Staff Deficiency
Letter from The NASDAQ Stock Market. The NASDAQ Letter states that for the
last 30 consecutive business days, the closing bid price per share for the
Company's common stock has been below the $1.00 minimum per share requirement
for continued inclusion under NASDAQ Marketplace Rule 4450(a)(5).

    In accordance with NASDAQ Marketplace Rule 4450(e)(2), Insmed will be
provided 180 calendar days, or until December 17, 2007, to regain compliance
by maintaining a closing bid price per share of $1.00 or higher for a minimum
of 10 consecutive business days. If Insmed is unsuccessful in meeting the
minimum bid requirement during this initial compliance period the Company may
transfer the listing of its shares of common stock to The NASDAQ Capital
Market and receive an additional 180 day compliance period if the Company
meets all initial listing criteria, except for the minimum bid requirement,
for that market as set forth in Marketplace Rule 4310(c). If Insmed does not
demonstrate compliance within the required period the Company will be issued a
delisting letter, which may be appealed at that time. The NASDAQ Letter
received on June 18, 2007 has no effect on the listing of the Company's common
stock at this time. The Company will seek to regain compliance within this
cure period and is considering alternatives to address compliance with the
continued listing standards of The NASDAQ Stock Market.

    About Insmed

    Insmed is a biopharmaceutical company focused on the development and
approval of drugs for the treatment of metabolic diseases with unmet medical
needs. For more information, please visit

    Forward-Looking Statements

    This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, the
Company may lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies differently than the
Company, competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical industry may
experience negative market trends and other risks and challenges detailed in
the Company's filings with the U.S. Securities and Exchange Commission,
including the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance on any
forward-looking statements which speak only as of the date of this release.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.

For further information:

For further information: Investor Relations International Haris Tajyar,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890